Search for: "Bristol-Myers Squibb" Results 201 - 220 of 863
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Apr 2016, 10:57 am by Dr. Shezad Malik
Nicholas Meyer recently filed against Bristol-Myers Squibb and Otsuka Pharmaceutical Co. in the U.S. [read post]
12 Aug 2011, 12:20 pm
Li works as a chemist for Bristol Myers Squibb. [read post]
19 Aug 2011, 6:30 am
Stanford University researchers recently reported a new drug interaction between paroxetine (Paxil, GlaxoSmithKline) and pravastatin (Pravachol, Bristol-Myers Squibb), which may lead to diabetes in prone individuals, or worsen present diabetes cases. [read post]
3 Feb 2010, 2:39 am by Mark Zamora
Didanosine, marketed by Bristol-Myers Squibb under the brand names Videx and Videx EC (an extended release version), was approved by the FDA in 1991, joining AZT as the only drugs then approved to treat HIV. [read post]
21 Nov 2010, 9:02 pm by Patent Docs
Bristol-Myers Squibb Co. 2:10-cv-00497; filed November 18, 2010 in the Eastern District of Texas False marking based on BMS' marking of its Cefzil products, its Buspar products, and its Pravachol products U.S. [read post]
10 Dec 2018, 5:01 am by Kit Case
ZymoGenetics, after being purchased by Bristol-Myers Squibb, has been winding down their Seattle presence, first noted when they chose to not renew their lease of the historic Lake Union Steam Plant building in 2016. [read post]
12 Feb 2018, 12:05 pm by Tom Lamb
Continuing, this Kombiglyze / Onglyza MDL Transfer Order sets forth the JPML's take on that contention by AstraZeneca, Bristol-Myers Squibb, and McKesson: Defendants concede that most cases involve allegations of heart failure, which is squarely in line with the results of the SAVOR study and the subsequent label change for Onglyza and Kombiglyze XR in April 2016. [read post]
8 Apr 2019, 9:59 pm by Patent Docs
Increases were notanle for Bristol Myers-Squibb and Takeda, while Sanofi and Gilead showed reduced sales. [read post]
18 Sep 2021, 8:45 pm by Patent Docs
.; Henry Hadad of Bristol-Myers Squibb; Joshua Rosenkranz of Orrick, Herrington & Sutcliffe LLP; and John Whealan of The George Washington... [read post]
5 Dec 2021, 9:36 pm by Patent Docs
Elsby of Akin Gump will moderate a panel consisting of Paul Golian of Bristol Myers Squibb and Paula Fritsch of Amgen. [read post]
30 Mar 2019, 8:49 pm by Patent Docs
Neal Dahiya of Bristol-Myers Squibb Company; Michael Flibbert of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; Michael Rosato of Wilson Sonsini Goodrich & Rosati will also address strategies for obtaining, and opposing, appellate standing. [read post]
14 Jun 2013, 9:22 pm by Patent Docs
Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff; and Paul Golian, Assistant General Counsel at Bristol-Myers Squibb Company will consider such questions as: • How many and which existing gene patents will be challenged in post-grant proceedings at the USPTO? [read post]